Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators "SPINAF"


Phase N/A Results

Trial Description

To study the effects of low-intensity anticoagulation with warfarin in comparison with a placebo for primary stroke prevention in patients with nonrheumatic atrial fibrillation.


  • Warfarin (Coumadin┬«)Drug
    Intervention Desc: Anticoagulant (Vitamin K antagonist)

Trial Design

Prospective, randomized, double-blind, placebo-controlled, trial of 571 men at 16 Department of Veterans Affairs medical centers.

Patient Involvement

Patients were randomized to receive adjusted-dose warfarin with a target prothrombin time ratio of 1.2 -1.5 (estimated INR equivalent of 1.4-2.8) or placebo for the duration of the study.


Type Measure Time Frame Safety Issue
Primary Cerebral infarction.
Secondary Cerebral hemorrhage and death.


Department of Veterans Affairs Cooperative Studies Program